|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0002351,
umls-concept:C0013227,
umls-concept:C0024826,
umls-concept:C0030705,
umls-concept:C0237463,
umls-concept:C0239307,
umls-concept:C0242656,
umls-concept:C0332293,
umls-concept:C0680281,
umls-concept:C0683325,
umls-concept:C1174995,
umls-concept:C1382107,
umls-concept:C1518527
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-5-17
|
|
pubmed:abstractText |
The withdrawal of marketing authorization for efalizumab by the European Medicines Agency in February, 2009 provided a unique opportunity to assess the course of disease in patients who were not subject to the selection criteria and biases that were common in the pivotal trials. The aim of this study was to evaluate the course of psoriasis following forced suspension of efalizumab in a group of patients treated in normal clinical practice. As secondary objectives, we sought to assess the relationships between clinical characteristics, treatment response, and disease course during efalizumab treatment and 12 and 24 weeks after suspension.
|
|
pubmed:language |
spa
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1578-2190
|
|
pubmed:author |
pubmed-author:BelinchónII,
pubmed-author:CarrascosaJ MJM,
pubmed-author:CarreteroGG,
pubmed-author:DaudénEE,
pubmed-author:FerránMM,
pubmed-author:FerrándizCC,
pubmed-author:FonsecaEE,
pubmed-author:García-BustinduyMM,
pubmed-author:Grupo Español de Psoriasis,
pubmed-author:López-EstebaranzJ LJL,
pubmed-author:MarrónS ESE,
pubmed-author:MorellLL,
pubmed-author:Muñoz-SantosCC,
pubmed-author:PuigLuisL,
pubmed-author:Sánchez-RegañaMM
|
|
pubmed:copyrightInfo |
2010 Elsevier España, S.L. y AEDV. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
102
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
354-64
|
|
pubmed:meshHeading |
pubmed-meshheading:21530928-Adolescent,
pubmed-meshheading:21530928-Adult,
pubmed-meshheading:21530928-Aged,
pubmed-meshheading:21530928-Aged, 80 and over,
pubmed-meshheading:21530928-Antibodies, Monoclonal,
pubmed-meshheading:21530928-Disease Progression,
pubmed-meshheading:21530928-Europe,
pubmed-meshheading:21530928-Humans,
pubmed-meshheading:21530928-Middle Aged,
pubmed-meshheading:21530928-Psoriasis,
pubmed-meshheading:21530928-Retrospective Studies,
pubmed-meshheading:21530928-Safety-Based Drug Withdrawals,
pubmed-meshheading:21530928-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
[Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European medicines agency: a multicenter observational study].
|
|
pubmed:affiliation |
Servicio de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España. laiamorell@hotmail.com
|
|
pubmed:publicationType |
Journal Article,
English Abstract,
Multicenter Study
|
